Abbvie Header week 48

Abbvie Header week 48

X

Digital content for Quotient Sciences

Quotient Sciences

QUOTIENT SCIENCES

About, Contact Details

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

Corporate Presentation, Oxilio & Quotient Announce Regulatory Approval for OXL001, Expansion of Facilities for Translational Pharmaceutics® Programs, Ensysce Biosciences & Quotient Announce a Partnership, Human ADME Studies, Bioanalytical Services, Translational Pharmaceutics®, Formulation Strategies for Poorly Soluble Molecules, Global Formulation Development & Manufacturing Capabilities, Commercial Manufacturing, Clinical Trial Manufacturing, Global Clinical Trial Supplies, GMP Certificate 2019, Financial Impact of Translational Pharmaceutics®, High Potency Handling, Project Management at Quotient Sciences, Pediatrics Services, Formulation Development, Clinical Pharmacology

VIDEO(s)

Corporate Video, Our Manifesto, Miami Clinical Pharmacology Facility

DIGITAL CONTENT

1 Interview #SpeakPharma, 99 News

DEVELOPMENTS

9 Drug(s) in Development

9 Drug(s) in Development

SERVICES

All Services, Analytical, Clinical Trials, API Manufacturing, Drug Product Manufacturing, API & Drug Product Development, Packaging

KEY SERVICES

Pharmacy Compounding Services, Pharmacy Compounding & Formulation Services, Formulation Development of Capsules, Development of Nasal Dosage Forms, Development of Pediatric Formulations, CDMO for Suspensions, Drug Substance Synthesis and Manufacturing

Pharmacy Compounding Services
Pharmacy Compounding & Formulation Services
Formulation Development of Capsules
Development of Nasal Dosage Forms
Development of Pediatric Formulations
CDMO for Suspensions
Drug Substance Synthesis and Manufacturing

INSPECTIONS & REGISTRATIONS

6 FDA, 7 EDQM, 1 GDUFA

All #SpeakPharma

“For orphan drugs, we identify a patient-ready formulation in less than half the time.”

Subscribe

“For orphan drugs, we identify a patient-ready formulation in less than half the time.”

Impressions: 3998

This week, SpeakPharma interviews Dr. Peter Scholes, Chief Scientific Officer, Quotient Sciences, who talks about orphan drugs and some of the challenges drug developers face while developing them. In particular, Dr. Scholes tells us how Quotient Sc...

#SpeakPharma With Quotient Sciences

08 Feb 2021

Contact Supplier

Quotient rm 250x250

8th Winter Process Chemistry Conf.

Attending

envelop Contact Supplier

Market Place

Home

Menu

Post Enquiry

Market Place

Search